Premium
Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase ‐ 4 inhibitor development
Author(s) -
Carr R. D.
Publication year - 2016
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.13066
Subject(s) - medicine , pharmacology , dipeptidyl peptidase , dipeptidyl peptidase 4 , endocrine system , drug development , ace inhibitor , drug , dipeptidyl peptidase 4 inhibitor , glucagon , enzyme inhibitor , glucagon like peptide 1 , diabetes mellitus , insulin , angiotensin converting enzyme , endocrinology , enzyme , hormone , type 2 diabetes , biochemistry , biology , blood pressure
The dipeptidyl peptidase ‐ 4 ( DPP ‐ 4) inhibitor concept is an example of prospective drug design and development based upon a distinct endocrine hypothesis. The design of enzyme inhibitors is a pragmatic approach to drug design; being compatible with the identification and optimization of small molecules that have properties commensurate with oral administration, as well as acceptable drug metabolism, distribution and elimination characteristics. Glucagon‐like peptide 1 ( GLP ‐ 1), a hormone with a spectrum of favourable metabolic actions, including glucose‐dependent stimulation of insulin and inhibition of glucagon secretion, provided the endocrine basis from which the idea of using DPP ‐ 4 inhibitors as anti‐diabetic agents was developed. The origin of the DPP ‐ 4 inhibitor concept was inspired by the angiotensin‐converting enzyme inhibitor approach, which succeeded in establishing a class of extensively used therapeutic agents for the treatment of cardiovascular disorders.